Third Rock Ventures News and Activities

View the org chart displaying its 34 main executives

Most searched biographies at Third Rock Ventures

• Robert Tepper, Founding Partner, Formation, Development and Scient...
• Chris Robinson, Chief Talent Officer
• Kevin Gillis, Partner and Chief Operating Officer

Create your alert
to follow the executive moves at Third Rock Ventures.

Third Rock Ventures has 1,642 competitors including Griffin Gaming Partners (United States (USA)), BlackRock (United States (USA)) and KKR (United States (USA)).

Popular M&A news in Fund

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (posted on June 3 2026).
• Prime Capital Financial has acquired Access Capital Partners (posted on June 2 2026).
• Frazier Healthcare Partners has acquired Altruix (posted on May 29 2026).

Popular contacts in Fund

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director at Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director at KKR

Learn more about the Fund industry

Press releases by Third Rock Ventures

• Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference » Rapport Therapeutics, Inc.
• Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | Tango Therapeutics, Inc
• Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update » Rapport Therapeutics, Inc.
• Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results - Mon, 05/11/2026 - 16:01
• Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Maze Therapeutics
• Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting » Rapport Therapeutics, Inc.
• Clasp Therapeutics Unveils First-in-Class KRas T Cell Engager CLSP-5282 at AACR 2026 — Clasp Tx
• Maze Therapeutics Announces $150 Million Registered Offering | Maze Therapeutics
• Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - Mon, 04/13/2026 - 08:00
• Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia | Terremoto
• View more press releases Close

Social media about Third Rock Ventures

• Third Rock Ventures on Wikipedia, Google News & Yahoo Finance
• Third Rock Ventures on LinkedIn, X (Twitter) & YouTube